drugset / Trial / NCT05324449

Epidiolex® for Anxiety in Pediatric Epilepsy

NCT05324449

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.

Timeline

Start
2022-04-05
Primary completion
2025-03-17
Completion
2025-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 100 mg/ml

Indications